Need immediate assistance? Call 1-518-730-0559 (Us-Canada Toll Free) or Contact Us

 

Global Breast Cancer Therapeutics Market Driven by Elevated Incidence in North America

Article Description

The global breast cancer therapeutics market is projected to expand significantly in the coming few years. Players in the global breast cancer therapeutics market will benefit from the opportunities presented by technological advancements and the robust rise in drug approval. Drug therapy for triple negative (TNBC) and new companion diagnostics models will also provide significant opportunities to companies.

The key companies operating in the global breast cancer therapeutics market are Sanofi, Teva Pharmaceutical Industries, Pfizer, Puma Biotechnology, Novartis International, GlaxoSmithKline, Hoffman-La Roche, Eli Lilly and Company, and AstraZeneca. Players in the market will also benefit from the rising demand for combination drug therapy. Apart from these trends, the global breast cancer therapeutics market will also benefit from several other drivers.

Browse the full Global Breast Cancer Therapeutics Market report at http://www.mrrse.com/breast-cancer-therapeutics-pipeline-analysis-market

Rising Incidence of Breast Cancer to Drive Global Breast Cancer Therapeutics Market

The global breast cancer therapeutics market will be driven by the increasing incidence of breast cancer observed worldwide. According to the National Cancer Institute, in 2012, 2,975,314 women had breast cancer in the U.S. alone. In addition to this, the global breast cancer therapeutics market will also be driven by the growing prevalence of obesity and the rise in private health insurance plans.

Moreover, trends such as demographic transitions and the increasing number of diagnostic screening programs will also positively impact the global breast cancer therapeutics market. In North America, the demographic transition has reached the final stage – low fertility/low mortality.

Serious Side Effects of Therapeutics to Challenge Market

Although the global breast cancer therapeutics market is driven by the aforesaid factors, it will be challenged by several factors. The serious side effects of breast cancer therapeutics will significantly hamper the global breast cancer therapeutics market. Furthermore, the global breast cancer therapeutics market will also be challenged by the newer medication options and access barriers due to the high cost of drugs.

In addition to this, the competition between generic drugs and substitute branded drugs will also suppress the global breast cancer therapeutics market. Other trends that will restrain the global breast cancer therapeutics market are the absence of social health insurance and the lack of women empowerment in many countries.

HER2 Inhibitors to Lead Global Breast Cancer Therapeutics Market

On the basis of drug class, the global breast cancer therapeutics market is segmented into hormone receptors, aromatase inhibitors, anti-metabolites, mitotic inhibitors, and HER2 inhibitors. Presently, the HER2 inhibitors segment is leading the global breast cancer therapeutics market and is projected to continue its dominance till 2023.

According to region, the global breast cancer therapeutics market is classified into North America, Asia Pacific, Europe, Latin America, and the Middle East and Africa. In 2014, North America led the global breast cancer therapeutics market. This regional market benefits from its favorable insurance system, entitling the high price of products. Furthermore, the entry of key pharmaceutical firms in the U.S. and the elevated prevalence of breast cancer will also drive this regional market in the foreseeable future. On the other hand, Asia Pacific is projected to witness the fastest growth in the global breast cancer therapeutics market in the coming few years.